Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Newer beta blockers and the treatment of hypertension.

Literature DB >> 1678961

Newer beta blockers and the treatment of hypertension.

D McAreavey¹, R Vermeulen, J I Robertson.

Abstract

Beta-adrenoceptor blocking agents are established as one of the principal classes of antihypertensive agents. Despite progressive refinements over the years, they still possess some unwanted effects, which limit their considerable value. In recent years a wide range of variations upon the beta-blocker theme has been developed. The full clinical advantages of the newer agents remain to be defined.

Entities: Disease

Mesh：

Substances：

Year: 1991 PMID： 1678961 DOI： 10.1007/bf03029727

Source DB: PubMed Journal: Cardiovasc Drugs Ther ISSN： 0920-3206 Impact factor: 3.727

95 in total

1. Haemodynamic effects of bisoprolol in patients with coronary heart disease: influence of various bisoprolol plasma concentrations.

Authors: J Bonelli; H Staribacher
Journal: J Cardiovasc Pharmacol Date: 1986 Impact factor: 3.105

2. Dose-effect relationship of carvedilol in essential hypertension. An open study.

Authors: T Ogihara; Y Goto; K Yoshinaga; Y Kumahara; O Iimura; M Ishii; E Murakami; T Takeda; T Kokubu; K Arakawa
Journal: Drugs Date: 1988 Impact factor: 9.546

3. Regression of left ventricular hypertrophy in treated hypertensive patients with dilevalol and metoprolol--a double blind randomized study.

Authors: S P Glasser; D K Koehn; R Powell
Journal: J Clin Pharmacol Date: 1989-09 Impact factor: 3.126

4. A placebo-controlled double-blind multicenter study of celiprolol in the treatment of mild and moderate hypertension.

Authors: P Capone; R Mayol
Journal: J Cardiovasc Pharmacol Date: 1986 Impact factor: 3.105

5. Echocardiographic studies of regression of left ventricular hypertrophy in hypertension.

Authors: F M Fouad-Tarazi; P R Liebson
Journal: Hypertension Date: 1987-02 Impact factor: 10.190

6. Antihypertensive effects of bunitrolol in essential hypertension.

Authors: M Yoshimura; R Shikuma; R Takashina; K Takeda; H Takahashi; H Ijichi; Y Kajita; H Yamazaki
Journal: Arzneimittelforschung Date: 1983

7. How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism.

Authors: A J Man in 't Veld; M A Schalekamp
Journal: Br J Clin Pharmacol Date: 1982 Impact factor: 4.335

8. Regression of cardiovascular structural changes by antihypertensive treatment. Functional consequences and time course of reversal as judged from clinical studies.

Authors: B Trimarco; J Wikstrand
Journal: Hypertension Date: 1984 Nov-Dec Impact factor: 10.190

Newer beta blockers and the treatment of hypertension.

1. Haemodynamic effects of bisoprolol in patients with coronary heart disease: influence of various bisoprolol plasma concentrations.

2. Dose-effect relationship of carvedilol in essential hypertension. An open study.

3. Regression of left ventricular hypertrophy in treated hypertensive patients with dilevalol and metoprolol--a double blind randomized study.

4. A placebo-controlled double-blind multicenter study of celiprolol in the treatment of mild and moderate hypertension.

5. Echocardiographic studies of regression of left ventricular hypertrophy in hypertension.

6. Antihypertensive effects of bunitrolol in essential hypertension.

7. How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism.

8. Regression of cardiovascular structural changes by antihypertensive treatment. Functional consequences and time course of reversal as judged from clinical studies.

9. Noninvasive assessment of left ventricular performance after administration of bisoprolol.

10. The Australian therapeutic trial in mild hypertension. Report by the Management Committee.

Review 1. Choosing the right beta-blocker. A guide to selection.

2. Effects of beta-blockers on HMG CoA reductase and LDL receptor activity in cultured human skin fibroblasts.